TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cardiac output max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve of plasma fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in number of standard drinks per drinking day
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Posttraumatic Stress Disorder Symptoms (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Posttraumatic Stress Disorder Symptoms (Clinician-Administered Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Cycle 1 and 2 Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Serum of Nanoparticle Albumin-bound Rapamycin Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet related behavior change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food security status
Endpoint domain: Life impact
Endpoint subdomain: N/A
Primary endpoint: Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: COVID-19 positive case
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Severe haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance between QFT-G assay and tuberculin skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Correlation of test results to patient's risk of LTBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of the Oncoral® test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Confirmed Morbidity or Mortality Event
Endpoint domain: Mortality/survival
Primary endpoint: Change in BMI Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Surface Temperature Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of community hypertension patients receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of community diabetes mellitus patients receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in UPSIT-40 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of an abnormal apnoea-hypnoea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in Average Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety severity measured by GAD-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain relief measured by visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo aneuploidies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Clinical Dementia Rating (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Ability to target representative sites of tumor grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Situation anxiety measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histologic Improvement at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With VGPR or Better Response to Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of CD34+ HPCs
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of CHESS criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Bioavailability of PBT2 (F%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MRI derived parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Depression ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient reported oral health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average inspiratory duty cycle in subjects with airway hyper-responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average inspiratory duty cycle in subjects without airway hyper-responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: risk of thyroid disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: COPD Self-Efficacy Scale (CSES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Care Agency Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Bleeding Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission (CR)-rate after induction therapy
Endpoint domain: Mortality/survival
Primary endpoint: Relapse-free survival, one year after consolidation therapy
Endpoint domain: Mortality/survival
Primary endpoint: Average number of days until healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs of Using the Interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Confirmed Biochemical Recurrence (BCR)-Free Rate at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Maintained Testosterone Level Less Than (<) 50 Nanograms Per Deciliter (ng/dL) Through Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Patients Surviving Without Disease Progression After 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Vascular graft infection
Endpoint domain: Adverse events/effects
Primary endpoint: aerobic capacity measurement with peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: GAD-7 anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hospital output
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of contrast-induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hepatitis C treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Surgical Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in best overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Ocular Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of retrospectively recruited CRC cases
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skin Reaction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Establishment of MTD for YQ23
Endpoint domain: Adverse events/effects
Primary endpoint: Success or failure of endodontic treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major depressive disorder response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major depressive disorder remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological state of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change of EMG-recorded Motor-evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dental neglect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of histology features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory markers in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arrhythmic Sudden Death
Endpoint domain: Mortality/survival
Primary endpoint: Hamilton Anxiety Rating Scale (HARS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton Depression Rating Scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fracture reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of gastric cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Had One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal temperature during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Bech-Rafaelsen Mania Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 expression as measured by PD-L1 tracer uptake on PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of ataxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait velocity (cm/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Redness at 60 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Response to Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero till 24 hours postdose (AUC 0-24h) of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dilantin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast Growth Factor 23 (FGF23) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Fitting Modifications to Optimize Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of GH and IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to complete or partial remission of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Patients With Major Bleeding Events (MBE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Symptomatic Venous Thromboembolic Events (sVTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Controlled Serum Phosphorous Levels on Lanthanum Carbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in MDS-UPDRS Parts II and III Combined Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trunk Percent Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leakage Under the Baseplate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin from baseline to after the final dose of study medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patients satisfaction with monovision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of severity of obstructive sleep apnea (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of severity of obstructive sleep apnea (95th percentile pressures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diet quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of epithelium vs stroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BPRS total and subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in SANS total and subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Prolactin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Supine vital signs (blood pressure and pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Cardiovascular (CV) Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of post-stroke sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of BMS-582664 on hepatic impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Growth Motor Function Measure Scale (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2D, video based gait assessment system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Mesalamine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Metabolite (N-acetyl-mesalamine) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Individual Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in minimum oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Respiratory Disturbance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in peak end-tidal carbon dioxide(CO2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in mean end-tidal carbon dioxide(CO2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amniotic membrane retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in American Orthopaedic Foot & Ankle Society (AOFAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Foot and Ankle Disability Index (FADI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetal death and/or preterm delivery
Endpoint domain: Mortality/survival
Primary endpoint: Plaque Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse plaque features
Endpoint domain: Adverse events/effects
Primary endpoint: Depression, Anxiety and Stress Scale-21 (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Warwick-Edinburgh Mental Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Hospitalized for COVID-19 But Not Intubated
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity as assessed by CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of terminally ill cancer patients receiving parenteral hydration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Predictability of orthodontic movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers (serum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid analysis (serum and DBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events - All Grades
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of STOPAIN in reducing migraine symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hemoglobin level test for fatigue assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: White blood cells count test for immunity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Scores During Overall IUD Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain During Tenaculum Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Measurement During Liquid Infusion/Sounding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain During IUD Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of newborns with HAI antibody titers of ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antioxidant variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-inflammatory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial progenitor cells (EPCs) number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ocriplasmin Activity Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change of B Type Natriuretic Peptides (BNP) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain NRS (numeric rating scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laryngospasm ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of the iON device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Mn deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Distance Visual Acuity (VA) - High Illumination High Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tidal Breathing Carbon Dioxide (TBCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age at menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean completion time for timed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Incontinence Impact Questionnaire (IIQ-7) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Urogenital Distress Inventory (UDI-6) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Incontinence Quality of Life (I-QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Overactive Bladder (OAB-V3) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of ipsilateral arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes